EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
4 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| lurbinectedin EU/3/23/2774 17 clinical trials → |
Treatment of soft tissue sarcoma | Active (positive) | 21 Apr 2023 |
| lurbinectedin EU/3/21/2495 17 clinical trials → |
Treatment of malignant mesothelioma | Active (positive) | 20 Aug 2021 |
| lurbinectedin EU/3/19/2143 · now authorised as Zepzelca 17 clinical trials → |
Treatment of small cell lung cancer | Active (positive) | 26 Feb 2019 |
| lurbinectedin EU/3/12/1053 17 clinical trials → |
Treatment of ovarian cancer | Active (positive) | 10 Oct 2012 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.